Do you lose your hair with Perjeta?
Pertuzumab and trastuzumab do not usually cause people to lose their hair. Any hair loss caused by chemotherapy should be temporary and in most cases your hair will begin to grow back once your chemotherapy has ended.
How long does Herceptin and Perjeta work?
Bottom Line. For the treatment of HER2+ early breast cancer, Perjeta treatment is usually continued for one year (up to 18 cycles) along with Herceptin treatment. These medications are given in the clinic on the same day. You will receive these medicines through your vein by an intravenous (IV) infusion.
Does Herceptin and Perjeta have side effects?
Diarrhea was the most severe side effect in both treatment groups and happened almost always during chemotherapy treatment: 9.8% of women in the Perjeta treatment group had severe diarrhea. 3.7% of women in the standard treatment group had severe diarrhea.
How long can you take Perjeta?
Perjeta treatment (when used either before or after surgery) usually lasts for a total of 18 cycles (up to one year) for patients with HER2+ early breast cancer (EBC) at high risk of recurrence. Your doctor may need to stop treatment early due to side effects or disease recurrence, whichever occurs first.
Is PERJETA a chemotherapy?
Perjeta (chemical name: pertuzumab) used in combination with Herceptin (chemical name: trastuzumab), another targeted therapy medicine, and Taxotere (chemical name: docetaxel), a type of chemotherapy, to treat HER2-positive, metastatic breast cancer that hasn’t been treated with either Herceptin or chemotherapy yet.
Can PERJETA cause neuropathy?
Perjeta (chemical name: pertuzumab), Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine), and Ogivri (chemical name: trastuzumab-dkst), targeted therapies, can also cause neuropathy.
Is perjeta a chemotherapy?
Is perjeta chemo or immunotherapy?
Phesgo (chemical name: pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a fixed-dose combination of Herceptin (chemical name: trastuzumab), Perjeta (chemical name: pertuzumab), and hyaluronidase-zzxf to treat all stages of HER2-positive breast cancer in combination with chemotherapy.
Is Perjeta a chemotherapy?
Does Herceptin and Perjeta make you sick?
The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are diarrhea, hair loss, low levels of white blood cells with or without fever, nausea, feeling tired, rash, and damage to the nerves (numbness, tingling …
Who gets PERJETA?
Most people get Perjeta every 3 weeks for 18 to 25 months. Women who are pregnant or are planning to get pregnant should not be given Perjeta. Perjeta can cause embryo death and birth defects. It’s important that you don’t get pregnant while you’re getting Perjeta; you must use effective birth control.
Can Herceptin and PERJETA cause neuropathy?
The most commonly reported adverse events that have occurred in patients on pertuzumab include diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy (Table 1).
Does Perjeta cause hair loss?
Hair loss is found among people who take Perjeta, especially for people who are female, 50-59 old , have been taking the drug for 1 – 6 months, also take medication Herceptin , and have Breast cancer female.
Does Perjeta cause headaches?
In BERENICE, when PERJETA was administered in combination with trastuzumab and paclitaxel for 4 cycles following 4 cycles of ddAC, the most common adverse reactions (> 30%) were nausea, diarrhea, alopecia, fatigue, constipation, peripheral neuropathy and headache.
Can Perjeta cause tiredness?
Common Perjeta side effects are more likely to occur, such as: nausea, diarrhea; temporary hair loss; fever, low blood cell counts; tiredness; rash; or. numbness, tingling, or burning pain in your hands or feet. This is not a complete list of side effects and others may occur.
Can Perjeta cause neuropathy?
Perjeta (chemical name: pertuzumab), Ibrance (chemical name: palbociclib), Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine), and Ogivri (chemical name: trastuzumab-dkst), targeted therapies, can also cause neuropathy.